Please ensure Javascript is enabled for purposes of website accessibility

Why Shockwave Medical Surged as High as 10% Today

By Eric Volkman – Aug 9, 2021 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Top- and bottom-line beats plus raised guidance made for a very healthy stock on Monday.

What happened

Shockwave Medical's (SWAV 0.08%) latest earnings release wasn't exactly a shocker, given the growing popularity of its products. Still, it put a real zip in the company's shares. They rose as high as 10% on Monday before settling down to a 3.8% gain on the day.

So what

For its Q2, Shockwave -- a healthcare company that makes sonic-wave devices that break up calcium deposits in the body -- earned revenue of just under $56 million, a more than fivefold increase from Q2 2020. The company's net loss narrowed considerably, landing at roughly $425,000 ($0.01 per share) against the year-ago deficit of $18.1 million.

A masked patient conferring with a masked doctor.

Image source: Getty Images.

According to data compiled by Zack's, the collective analyst estimate for the latter metric was far deeper, at $0.41. Shockwave's revenue topped those prognosticators' average projection by nearly 30%.

Shockwave attributed this success to the rapid take-up of its core technology, which is known technically as intravascular lithotripsy (IVL). It quoted CEO Doug Godshall as saying, "The growing clinical acceptance of IVL continues to validate the importance of IVL for our customers and their patients and for the treatment of calcified arterial disease."

Now what

Shockwave believes this momentum will keep building, and obviously investors agreed on Monday. The company upped its full-year revenue guidance considerably; it's now estimating it will book $218 million to $223 million for the year, up from the previous projection of $195 million to $205 million. The former range would represent year-over-year growth of at least 222% if realized. 

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Shockwave Medical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ShockWave Medical Stock Quote
ShockWave Medical
SWAV
$264.27 (0.08%) $0.21

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
356%
 
S&P 500 Returns
118%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.